Skip to content

Acceptance and Mindfulness Based Exposure Therapy for Survivors of Cardiac Arrest

Feasibility Pilot of Acceptance and Mindfulness Based Exposure Therapy for Survivors of Cardiac Arrest

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04596891
Acronym
AMBET
Enrollment
11
Registered
2020-10-22
Start date
2021-03-02
Completion date
2022-04-21
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest, PTSD

Brief summary

The primary goal of this uncontrolled pilot trial is to examine feasibility, acceptability, safety, and preliminary efficacy of a new behavioral treatment for survivors of sudden cardiac arrest with clinically elevated symptoms of post-traumatic stress disorder (PTSD). Participants will be recruited among cardiac arrest survivors enrolled in the observational CANOE research study (CUIMC IRB# AAAR8497). Study participants will be interviewed about their symptoms and evaluated for baseline assessment before receiving eight weekly sessions of an acceptance and mindfulness-based exposure therapy (AMBET). Participants will be additionally evaluated at treatment mid-point (week 4), and at the end of treatment. The treatment and all assessments will be conducted remotely via Zoom. To assess whether patients' physical activity is improved over the course of treatment, participants will be provided with a wearable device (Fitbit wristband) to monitor their physical activity. The specific aims of this study are to: (1) develop an acceptable protocol for an AMBET intervention for survivors of sudden cardiac arrest with elevated PTSD symptoms (2) examine its safety and feasibility in a small sample of 14 patients (3) investigate acceptability and feasibility of the assessments and measurements including physical activity.

Detailed description

Clinically elevated levels of PTSD symptoms occur in approximately 1 in 3 cardiac arrest survivors with intact cognitive function and are associated with increased risk for future cardiac events and mortality. Survivors of acute cardiovascular events are typically encouraged to monitor for somatic cues of cardiovascular activity that might indicate recurrent events. However, threat-related attention bias is a common sequela of trauma. In cardiac patients, this hypervigilant attention to interoceptive cues of danger may serve to maintain threat perception, as arousal amplifies awareness of internal stimuli. Elevated PTSD symptoms have also been associated with low adherence to physical activity and medication regiments in patients with elevated PTSD symptoms after other types of cardiovascular events in part because they can serve as traumatic reminders. Although several well-studied, validated treatments for PTSD exist, there is no evidence-based treatment for PTSD in cardiac arrest survivors. Standard PTSD interventions targeting fear extinction and threat perception in the context of current safety pose a problem in a population that is living with an actual ongoing cardiac threat. Thus, the investigators will be developing a de novo protocol for an Acceptance and Mindfulness-Based Exposure Therapy (AMBET) intervention that targets increased discriminatory perception through mindful interoceptive attention and adaptive threat responding. Initial evidence has been published to suggest the safety and potential efficacy of imaginal exposure in cardiac patients to reduce PTSD symptoms. Among PTSD treatments, exposure therapy is the most widely recommended. However, the efficacy is moderate, and high dropout rates are well documented. An innovative line of PTSD therapies can be found among mindfulness- and acceptance-based treatments. Although large scale RCTs are still limited, there are promising findings of treatment effects on reduced PTSD symptoms. Reported dropout rates have been low across treatments, indicating a high degree of treatment acceptability. The addition of mindfulness components to exposure therapy has been proposed to enhance the effects of exposure as well as the willingness to engage in them. Of particular interest for cardiac patients are findings that mindfulness-based approaches have normalized cortisol levels and reduced inflammatory biomarkers in PTSD patients, as these are physiological processes that have been implicated in the links between PTSD and cardiovascular risk. Several mechanisms have been posited to underlie the efficacy of mindfulness-based approaches including increased metacognitive awareness of interoceptive sensations and mind-body connections. Furthermore, and contrary to the associations found between hypervigilant interoceptive awareness and psychopathology, mindful attention to interoceptive cues has been linked with adaptive, resilience-enhancing behaviors. The goals of the AMBET treatment will be to reduce PSTD symptoms and hypervigilance to internal stimuli (i.e., interoceptive bias), and increase cardiovascular health behaviors (medication adherence, physical activity) following cardiac arrest. Following psychoeducation about PTSD and cardiovascular disease related health behaviors, participants will be engaged in in-vivo and imaginal exposure exercises to reduce avoidance responses. Participants will be introduced to acceptance and mindfulness-based strategies that will be practiced in session and as homework assignments. Eight 90 minute sessions will be delivered to patients individually on a weekly basis through HIPAA-compliant zoom-hosted video visits. Patient symptoms will be assessed by an independent evaluator before, at mid-point, and post-treatment. A within-subjects repeated measures design will be used to assess the feasibility of conducting all aspects of the study remotely, including recruitment, assessment, and treatment delivery.

Interventions

BEHAVIORALPsychotherapy

Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.

Sponsors

Columbia University
CollaboratorOTHER
Research Foundation for Mental Hygiene, Inc.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Males or females between the age of 18-85 2. A PCL-5 score of ≥ 33 at most recent assessment (≥ 30 days post cardiac arrest) 3. Hospitalization for cardiac arrest with cardiac etiology at any time in the past.

Exclusion criteria

1. Heart failure with severe systolic dysfunction (ejection fraction ≤ 25%) 2. Terminal non-cardiovascular illness with life expectancy \<1 year 3. History of psychiatric diagnosis of psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder 4. Current severe depression determined by a) a score of \>25 on the Hamilton Rating Scale for Depression (HAM-D-17-item), and b) clinical assessment. 5. Significant cognitive impairment defined by Cerebral Performance Category Score ≥3, and/or MMSE score of \<24 neurological impairment precluding ability to complete study questionnaires. 6. Active suicidal ideation or behavior. 7. Current primary diagnosis of bipolar disorder. 8. Current unstable or untreated medical illness. 9. Current drug or alcohol misuse: severe alcohol/cannabis or any other substance use disorder (except nicotine). 10. Recent psychotropic medication change or initiation within the last 3 months. 11. Initiation of other psychotherapy within the last 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Change in PTSD Symptoms Over TimeBaseline, At 4 weeks, Post-treatment: approximately 3 months from intakeReduction in symptoms as measured by the Clinician Administered PTSD Scale (Caps-5: ranging from 0-80 ) from pre- to post-treatment. Lower scores mean better outcome (reduction of symptom severity).
Change in Medication Adherence Over TimeEnd of treatment: approximately 3 months from intakeParticipants' cardiac medication adherence is measured by self-report using the Morisky Medication Adherence Scale (MMAS). Scores can range from 0-8. If a patient scores higher on the scale, they are evaluated as more adherent.
Change in Physical Activity Over TimeEnd of treatment: approximately 3 months from intakeParticipants level of physical activity is measured objectively by a wrist worn Fitbit device.

Secondary

MeasureTime frameDescription
Change in Interoceptive Attention Style Over TimeBaseline, Post-treatment: approximately 3 months from intakeChanges in hypervigilance driven interoceptive attention and acceptance/mindfulness-based attention will be measured by the Multidimensional Assessment of Interoceptive Awareness (MAIA). The scale consists of 8 scales (addressing 5 dimensions of body awareness)The MAIA consists of 8 scales (addressing 5 dimensions of body awareness): Noticing (0-20); Not-Distracting (0-30); Not-Worrying (0-25); Attention Regulation (0-35); Emotional Awareness (0-25); Self-Regulation (0-20); Body Listening (0-15); Trust (0-15). A total scale score is not relevant. Higher scores indicate better outcomes (increased adaptive interoceptive attention).
Participant Satisfaction With TreatmentEnd of treatment: approximately 3 months from intakeTreatment satisfaction will be measured by the Client Satisfaction Questionnaire (CSQ-3). Scores range from 0-12 with higher scores indication more satisfaction with treatment.
Change in Cardiac AnxietyBaseline, Post-treatment: approximately 3 months from intakeChange in cardiac anxiety from pre- to post-treatment assessment will be assessed using the Cardiac Anxiety Questionnaire (CAQ: score range: 0-72). Low scores mean better outcome (reduction in cardiac anxiety).
Proportion of Participants Who Complete the Study ProtocolEnd of treatment: approximately 3 months from intakePreliminary tolerability of the protocol will assessed by the number of enrolled participants who comply with all study procedures
Change in Depressive Symptoms Over TimeAt Baseline, At 4 weeks, Post-treatment: approximately 3 months from intakeChange in symptoms as measured by the Hamilton Depression Rating Scale (HDRS-17; range 0-52) from pre- to post-treatment. Lower scores indicate better outcomes (reduction in symptoms).

Countries

United States

Participant flow

Participants by arm

ArmCount
Intervention
Remotely delivered psychotherapy combining exposure therapy with mindfulness Psychotherapy: Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
11
Total11

Baseline characteristics

CharacteristicIntervention
Age, Continuous51.55 years
STANDARD_DEVIATION 9.1
Diagnosis at Baseline: Depression9 Participants
Diagnosis at Baseline: Posttraumatic Stress Disorder (PTSD)11 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
10 Participants
Sex: Female, Male
Female
7 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 11
other
Total, other adverse events
0 / 11
serious
Total, serious adverse events
0 / 11

Outcome results

Primary

Change in Medication Adherence Over Time

Participants' cardiac medication adherence is measured by self-report using the Morisky Medication Adherence Scale (MMAS). Scores can range from 0-8. If a patient scores higher on the scale, they are evaluated as more adherent.

Time frame: End of treatment: approximately 3 months from intake

Population: baseline conducted on all enrolled participants, posttreatment data available for 9 patients

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in Medication Adherence Over TimeBaseline3.18 score on a scaleStandard Deviation 1.83
InterventionChange in Medication Adherence Over TimePosttreatment2.38 score on a scaleStandard Deviation 1.41
Primary

Change in Physical Activity Over Time

Participants level of physical activity is measured objectively by a wrist worn Fitbit device.

Time frame: End of treatment: approximately 3 months from intake

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in Physical Activity Over TimeBaseline7109.83 daily stepsStandard Deviation 5377.75
InterventionChange in Physical Activity Over TimePosttreatment9296.83 daily stepsStandard Deviation 5600.44
Primary

Change in PTSD Symptoms Over Time

Reduction in symptoms as measured by the Clinician Administered PTSD Scale (Caps-5: ranging from 0-80 ) from pre- to post-treatment. Lower scores mean better outcome (reduction of symptom severity).

Time frame: Baseline, At 4 weeks, Post-treatment: approximately 3 months from intake

Population: Baseline, midpoint, and post-treatment analysis of symptom scores for participants who completed the study protocol.

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in PTSD Symptoms Over TimePosttreatment16.20 score on a scaleStandard Deviation 10.84
InterventionChange in PTSD Symptoms Over TimeBaseline37.00 score on a scaleStandard Deviation 7.05
InterventionChange in PTSD Symptoms Over TimeMidpoint (4 weeks)25.90 score on a scaleStandard Deviation 9.15
Comparison: No control group, open trial for feasibility/safetyp-value: <0.001ANOVA
p-value: 0.00295% CI: [-1.79, 12.93]t-test, 2 sided
Secondary

Change in Cardiac Anxiety

Change in cardiac anxiety from pre- to post-treatment assessment will be assessed using the Cardiac Anxiety Questionnaire (CAQ: score range: 0-72). Low scores mean better outcome (reduction in cardiac anxiety).

Time frame: Baseline, Post-treatment: approximately 3 months from intake

Population: treatment completers

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in Cardiac AnxietyBaseline36.67 score on a scaleStandard Deviation 9.67
InterventionChange in Cardiac AnxietyPosttreatment35.00 score on a scaleStandard Deviation 10.39
Secondary

Change in Depressive Symptoms Over Time

Change in symptoms as measured by the Hamilton Depression Rating Scale (HDRS-17; range 0-52) from pre- to post-treatment. Lower scores indicate better outcomes (reduction in symptoms).

Time frame: At Baseline, At 4 weeks, Post-treatment: approximately 3 months from intake

Population: Treatment completers.

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in Depressive Symptoms Over TimeBaseline17.27 score on a scaleStandard Deviation 6.36
InterventionChange in Depressive Symptoms Over TimeMidpoint (4 weeks)13.50 score on a scaleStandard Deviation 4.5
InterventionChange in Depressive Symptoms Over TimePosttreatment10.10 score on a scaleStandard Deviation 7.23
p-value: <0.001ANOVA
Secondary

Change in Interoceptive Attention Style Over Time

Changes in hypervigilance driven interoceptive attention and acceptance/mindfulness-based attention will be measured by the Multidimensional Assessment of Interoceptive Awareness (MAIA). The scale consists of 8 scales (addressing 5 dimensions of body awareness)The MAIA consists of 8 scales (addressing 5 dimensions of body awareness): Noticing (0-20); Not-Distracting (0-30); Not-Worrying (0-25); Attention Regulation (0-35); Emotional Awareness (0-25); Self-Regulation (0-20); Body Listening (0-15); Trust (0-15). A total scale score is not relevant. Higher scores indicate better outcomes (increased adaptive interoceptive attention).

Time frame: Baseline, Post-treatment: approximately 3 months from intake

Population: Treatment completers

ArmMeasureGroupValue (MEAN)Dispersion
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Body Listening Subscale5.00 score on a scaleStandard Deviation 2.61
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Noticing Subscale10.73 score on a scaleStandard Deviation 3.13
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Noticing Subscale11.56 score on a scaleStandard Deviation 3.57
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Not Distracting Subscale12.63 score on a scaleStandard Deviation 5.3
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Not Distracting Subscale10.22 score on a scaleStandard Deviation 4.29
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Not Worrying Subscale9.81 score on a scaleStandard Deviation 2.18
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Not Worrying Subscale8.56 score on a scaleStandard Deviation 2.79
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Attention Regulation Subscale15.73 score on a scaleStandard Deviation 4.88
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Attention Regulation Subscale15.67 score on a scaleStandard Deviation 4.15
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Emotional Awareness Subscale13.73 score on a scaleStandard Deviation 3.64
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Emotional Awareness Subscale14.44 score on a scaleStandard Deviation 4.07
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Self-Regulation Subscale7.00 score on a scaleStandard Deviation 2.61
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Self-Regulation Subscale8.56 score on a scaleStandard Deviation 2.65
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Body Listening Subscale6.78 score on a scaleStandard Deviation 2.17
InterventionChange in Interoceptive Attention Style Over TimeBaseline: Trust Subscale5.18 score on a scaleStandard Deviation 2.4
InterventionChange in Interoceptive Attention Style Over TimePosttreatment: Trust Subscale6.11 score on a scaleStandard Deviation 2.76
Secondary

Participant Satisfaction With Treatment

Treatment satisfaction will be measured by the Client Satisfaction Questionnaire (CSQ-3). Scores range from 0-12 with higher scores indication more satisfaction with treatment.

Time frame: End of treatment: approximately 3 months from intake

Population: Data is available for participants who attended post-treatment assessment.

ArmMeasureValue (MEAN)Dispersion
InterventionParticipant Satisfaction With Treatment10.9 score on a scaleStandard Deviation 1.3
Secondary

Proportion of Participants Who Complete the Study Protocol

Preliminary tolerability of the protocol will assessed by the number of enrolled participants who comply with all study procedures

Time frame: End of treatment: approximately 3 months from intake

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionProportion of Participants Who Complete the Study Protocol10 Participants

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026